On August 15, 2025 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported its financial results for the second quarter 2025 (Press release, AIM ImmunoTech, AUG 15, 2025, View Source [SID1234655331]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Through the second quarter, we continued to prioritize and accelerate our development efforts for Ampligen, particularly in our Phase 2 trial for locally advanced pancreatic cancer in collaboration with Erasmus Medical Center and AstraZeneca. We remain encouraged by the growing body of positive clinical data demonstrated to date and believe that as we build momentum, we are well positioned to execute on a clear path toward government approval. Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers, and our mission remains focused on making a meaningful difference in this space for patients," commented AIM Chief Executive Officer Thomas K. Equels.

Recent Highlights

Resumed trading on the NYSE American;
Closed public equity offering in July, raising $8.0 million in gross proceeds, which is expected to fund operations for approximately 12 months;
Reported positive data in a mid-year update from the ongoing Phase 2 DURIPANC clinical study evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX (See: NCT05927142);
Announced upcoming presentations at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care;
Ampligen oncology data was presented at scientific congresses including the Annual Meeting of the American Association of Immunologists and U.S.-Poland Science and Technology Symposium 2025.
For more information, please visit the Company’s website at aimimmuno.com.

Summary of Financial Highlights for Second Quarter 2025

As of June 30, 2025, AIM reported cash, cash equivalents and marketable investments of $835,000.
Research and development expenses for the three months ended June 30, 2025 were $1.2 million, compared to $1.1 million for the same period in 2024.
General and administrative expenses were $1.5 million for the three months ended June 30, 2025, compared to $2.6 million for the same period 2024.
The net loss from operations for the three months ended June 30, 2025 was $2.8 million, or $(3.68) per share, compared to $1.8 million, or $(3.00) per share, for the three months ended June 30, 2024.
Please refer to the full 10-Q for complete details.